Skip to content
Cyclodextrin News

Cyclodextrin News

A forum for researchers, students and applicants in the field of cyclodextrin technology

  • Home
  • Pharma applications
  • Non-pharma applications
  • CD derivatives
  • Events
  • E-ducation

Tag: cytotoxicity

March 20, 2025 Drug delivery / Pharma applications

Biopolymer Composite Materials as Drug Delivery Platforms for Regenerative Pharmacology

Frontiers in Pharmacology calls for papers in thematic issue: Biopolymer Composite Materials as Drug Delivery Platforms for Regenerative Pharmacology. Biopolymer

Continue reading

February 3, 2025 CD derivatives / Drug delivery / Life sciences / Pharma applications

Cyclodextrins unlock the full potential of lipopeptides — reducing cytotoxicity while keeping their antimicrobial efficacy intact

Over the past decade, the growing threat of antibiotic resistance has intensified interest in antimicrobial peptides and lipopeptides as promising

Continue reading

May 26, 2023 Drug delivery / Pharma applications

Ensembles of carboxymethyl cyclodextrins on cationic liposomes as highly efficient nanocontainers for the delivery of hydrophobic compounds

The increase of payload is one of the key tasks in creation of nanocontainers for the delivery of bioactive substances

Continue reading

June 2, 2022 CD derivatives / Gene delivery / Pharma applications

Tetraethylenepentamine-Coated β Cyclodextrin Nanoparticles for Dual DNA and siRNA Delivery

Tetraethylenepentamine-coated β-cyclodextrin (TEPA-BCD) nanoparticles were synthesized, characterized, and evaluated for targeted cell delivery of plasmid DNA and siRNA. The cationic

Continue reading

May 12, 2022 CD as API / Pharma applications

Cothreading of Unmodified and Monoazidated β-Mixed cyclodextrins in polyrotaxanes for Niemann Pick disease

To establish a method for the orthogonal chemical functionalization of β-cyclodextrin (β-CD)-based polyrotaxane (PRX), unmodified and monoazidated β-CDs (N3-β-CDs) were

Continue reading

Recent Posts

  • Events of American Cyclodextrin Consortium
  • Ultrafast-dissolving ocular microneedle patch with voriconazole-cyclodextrin complex
  • Nano-Enabled Toxicity of Pharmaceutical Excipients
  • Cyclodextrins Across the Eye-Care Spectrum
  • Biphasic dissolving microneedles with cyclodextrin inclusion complexes for enhanced delivery of poorly soluble drugs

Tags

alpha-CD atherosclerosis Cancer therapy Captisol Cholesterol Clinical trial conference Covid-19 cyclodextrin polymer Dexolve drug delivery drug delivery systems electrospinning FDA Food gamma-CD Gilead HPBCD hydrogel methyl BCD Nanoparticles Niemann Pick Disease RAMEB remdesivir review SBECD Special issue Sugammadex Synthesis

Follow Us

  • LinkedIn
  • X
  • Facebook

Categories

  • Agriculture (27)
  • Analysis (66)
  • CD as API (347)
  • CD derivatives (410)
  • Cosmetics and toilettry (51)
  • Diagnosis (12)
  • Drug delivery (790)
  • E-ducation (63)
  • Environmental (134)
  • Events (234)
  • Food (221)
  • Gene delivery (20)
  • Household products (4)
  • Household products (1)
  • In Hungarian (4)
  • Life sciences (42)
  • Non-pharma applications (399)
  • Other industrial use (106)
  • Pharma applications (1,182)
  • Supramolecular systems (40)
  • Uncategorized (146)

Top Posts

  • Cyclarity Unveils First-Ever Clinical Data Demonstrating Excretion of Oxidized Cholesterol, at American Heart Association Vascular Discovery Scientific Sessions
  • How air fresheners work?
  • β-Cyclodextrin functionalized agarose-based hydrogels for multiple controlled drug delivery of ibuprofen
  • Biphasic dissolving microneedles with cyclodextrin inclusion complexes for enhanced delivery of poorly soluble drugs
  • CD-based supramolecular polymers based on host–guest interactions for cancer therapy
  • Events of American Cyclodextrin Consortium
  • Use of cyclodextrins in diseases and disorders involving phospholipid dysregulation
  • Using cyclodextrin is not rocket science...except for NASA researchers.
  • 21st International Cyclodextrin Symposium - Deadline for abstract submission extended to February 14, 2024
  • Oculis aces the Phase 2 clinical trial for OCS-01 treating DME

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 4,472 other subscribers

Loading Comments...